ANGO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AngioDynamics Inc (ANGO) is not a strong buy for a beginner, long-term investor with $50,000-$100,000 available for investment at this time. While the company has shown some positive financial growth trends and analysts maintain a Buy rating with a price target of $16, the technical indicators and lack of significant positive catalysts suggest that the current price does not present an optimal entry point. The stock's recent performance and lack of strong trading signals further support a 'hold' recommendation.
The technical indicators for ANGO are mixed to bearish. The MACD histogram is below 0 and negatively contracting, suggesting weak momentum. The RSI is neutral at 53.096, and moving averages are bearish with SMA_200 > SMA_20 > SMA_5. Key support and resistance levels indicate limited upside potential in the short term, with a pivot at 10.487 and resistance at 11.458.
Analysts maintain a Buy rating with a price target of $16, citing an improved growth profile due to the company's pivot to higher-growth medical technology platforms. The company raised its revenue, adjusted EBITDA, and adjusted EPS guidance ranges for FY26.
Gross margin dropped by 1.73% YoY, and the company's net income remains negative despite improvements. Technical indicators are not supportive of a strong upward trend. No recent news or significant trading trends from hedge funds or insiders. Lack of recent Congress trading data.
In Q3 2026, revenue increased by 8.91% YoY to $78.42M. Net income improved by 83.44% YoY but remains negative at -$8.08M. EPS increased by 72.73% YoY to -0.19. Gross margin dropped slightly to 49.49%, down 1.73% YoY.
Freedom Broker initiated coverage with a Buy rating and a $16 price target, citing an improved growth profile. Canaccord lowered its price target from $18 to $16 but maintained a Buy rating, noting revenue beats and increased guidance despite concerns over adjusted EBITDA optics.
